Research
Hormonal
Randomized trials with liraglutide and semaglutide have shown reductions in major adverse cardiovascular events.
These medications may be beneficial for patients at high risk of cardiovascular events.
StrongSupportsmedium confidence
In high-risk populations, randomized trials with liraglutide and semaglutide have also shown reductions in major adverse cardiovascular events.
Why this rating
Based on randomized trials mentioned in the abstract.
Source
Cardiovascular effects of anti-obesity medications: the perils and promise
Haoyi Zheng · Cardiology Plus · 2025
reviewCited 4×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →